The comparative study of the wogonin network pharmacology against acute monocytic leukemia treatment (AML‐M5) indicated that wogonin was efficient on SRC, RELA, JUN, CCND1, TP53, HSP90AA1, AKT1, and PIK3R1 in the key genes. This evidence concerns the gene TP53 and acute myeloid leukemia.